Previous Close | 0.3000 |
Open | 0.3000 |
Bid | 0.0000 x 900 |
Ask | 0.0000 x 3000 |
Day's Range | 0.2998 - 0.3000 |
52 Week Range | 0.1400 - 0.7500 |
Volume | |
Avg. Volume | 3,561 |
Market Cap | 1.257M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.6900 |
Earnings Date | Aug 24, 2017 - Aug 25, 2017 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
EOM Pharmaceuticals, Inc. ("EOM"), a privately held, clinical-stage pharmaceutical company, and ImmunoCellular Therapeutics, Ltd. (OTC: IMUC) ("ImmunoCellular") today announced that the companies have entered into and closed on a merger agreement pursuant to which the shareholders of EOM are now the majority shareholders of the combined company. The merger will create a public company that will continue EOM's focus on advancing novel immunomodulatory and retinal disease drug agents to address a
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under the Securities and Exchange Act which will be applicable in September 2021. The amended Rule requires issuers that trade on the Over-the-Counter Link® Alternative Trading System or OTC Link ATS trading platform to make current information about the issuer publicly available. In advance of the deadline of June 30, 2021, ImmunoCellular has sub